A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL628 in Participants with Early Alzheimer’s Disease
DNLI-K-0001
Phase 1 other active
Quick answer
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL628 in Participants with Early Alzheimer’s Disease for Early Alzheimer's Disease is a Phase 1 program (other) at Denali Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Denali Therapeutics
- Indication
- Early Alzheimer's Disease
- Phase
- Phase 1
- Modality
- other
- Status
- active